Linked Life Data

16200338

Source:http://linkedlifedata.com/resource/pubmed/id/16200338

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
2005-10-3
pubmed:abstractText
Leukotrienes are potent proinflammatory mediators derived from of arachidonic acid through the 5- lipoxygenase pathway. Experimental data suggest a role for cysteinyl leukotrienes in the pathogenesis of atopic dermatitis and there is a rationale for the use of pharmacological agents to antagonize their effects in the treatment of atopic dermatitis. We report 2 cases of severe atopic dermatitis successfully treated with montelukast as a single therapeutic agent in a daily dose of 10 mg for 8 weeks when corticosteroid treatment was contraindicated or failed to control the disease. Our observations suggest that montelukast may be used as an alternative steroid sparing medication for severe atopic dermatitis, especially in patients with associated asthma and rhinitis.
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
1318-4458
pubmed:author
pubmed:issnType
Print
pubmed:volume
14
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
115-9
pubmed:meshHeading
pubmed:year
2005
pubmed:articleTitle
Successful treatment of severe atopic dermatitis with cysteinyl leukotriene receptor antagonist montelukast.
pubmed:affiliation
Department of Dermatology, University of Medicine, 1 S.G.Sofiiski Blvd, 1431 Sofia, Bulgaria. i.angelova_fischer@abv.bg
pubmed:publicationType
Journal Article, Case Reports